Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Anika Therapeutics (ANIK) Shares Outstanding (2016 - 2026)

Anika Therapeutics has reported Shares Outstanding over the past 17 years, most recently at $13.4 million for Q1 2026.

  • Quarterly Shares Outstanding fell 6.82% to $13.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $13.4 million through Mar 2026, down 6.82% year-over-year, with the annual reading at $15.4 million for FY2025, 6.72% up from the prior year.
  • Shares Outstanding was $13.4 million for Q1 2026 at Anika Therapeutics, down from $13.9 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $14.8 million in Q2 2024 and troughed at $14607.0 in Q3 2022.
  • The 5-year median for Shares Outstanding is $14.6 million (2022), against an average of $13.6 million.
  • Year-over-year, Shares Outstanding crashed 99.9% in 2022 and then surged 100105.38% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $14.6 million in 2022, then increased by 0.24% to $14.7 million in 2023, then dropped by 1.66% to $14.4 million in 2024, then rose by 6.72% to $15.4 million in 2025, then fell by 13.18% to $13.4 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Shares Outstanding are $13.4 million (Q1 2026), $15.4 million (Q4 2025), and $14.4 million (Q3 2025).